Construction of peptides with nucleobase amino acids: design and synthesis of the nucleobase-conjugated peptides derived from HIV-1 Rev and their binding properties to HIV-1 RRE RNA.
In order to develop a novel molecule that recognizes a specific structure of RNA, we have attempted to design peptides having L-alpha-amino acids with a nucleobase at the side chain (nucleobase amino acid (NBA)), expecting that the function of a nucleobase which can specifically recognize a base in RNA is regulated in a peptide conformation. In this study, to demonstrate the applicability of the NBA units in the peptide to RNA recognition, we designed and synthesized a variety of NBA-conjugated peptides, derived from HIV-1 Rev. Circular dichroism study revealed that the conjugation of the Rev peptide with an NBA unit did not disturb the peptide conformation. RNA-binding affinities of the designed peptides with RRE IIB RNA were dependent on the structure of the nucleobase moieties in the peptides. The peptide having the cytosine NBA at the position of the Asn40 site in the Rev showed a higher binding ability for RRE IIB RNA, despite the diminishing the Asn40 function. Furthermore, the peptide having the guanine NBA at the position of the Arg44 site, which is the most important residue for the RNA binding in the Rev, bound to RRE IIB RNA in an ability similar to Rev34-50 with native sequence. These results demonstrate that an appropriate NBA unit in the peptide plays an important role in the RNA binding with a specific contact such as hydrogen bonding, and the interaction between the nucleobase in the peptide and the base in the RNA can enhance the RNA-binding affinity and specificity.
Takahashi
T
T
Department of Bioengineering, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Japan.
Hamasaki
K
K
Ueno
A
A
Mihara
H
H
D000596:Amino Acids / Q000737:chemistry*; D016880:Anisotropy; D019380:Anti-HIV Agents / Q000138:chemical synthesis* / Q000494:pharmacology*; D002942:Circular Dichroism; D015497:HIV-1 / Q000737:chemistry* / Q000187:drug effects; D009705:Nucleosides / Q000737:chemistry*; D010455:Peptides / Q000138:chemical synthesis* / Q000494:pharmacology*; D012333:RNA, Messenger / Q000187:drug effects / Q000235:genetics; D012367:RNA, Viral / Q000187:drug effects* / Q000235:genetics; D020218:Response Elements / Q000187:drug effects*; D014764:Viral Proteins / Q000096:biosynthesis
D000596:Amino Acids; D019380:Anti-HIV Agents; D009705:Nucleosides; D010455:Peptides; D012333:RNA, Messenger; D012367:RNA, Viral; D014764:Viral Proteins